Phadke, Varun K. http://orcid.org/0000-0002-0318-4939
Scanlon, Nicholas
Jordan, Stanley C.
Rouphael, Nadine G.
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1-TR002378)
National Institute of Allergy and Infectious Diseases (5R38AI140299-02)
National Institutes of Health (5U19AI090023)
Article History
Accepted: 21 February 2021
First Online: 4 March 2021
Declarations
:
: Dr. Phadke was supported in part by Imagine, Innovate, and Impact (I3) Funds from the Emory University School of Medicine and through the Georgia CTSA NIH award (UL1-TR002378). Dr. Scanlon was supported by the NIH R38 Stimulating Access to Research in Residency (StARR) grant through the NIH/NIAID (5R38AI140299-02). Dr. Jordan reports receiving grants and non-financial support from CSL Behring during the preparation of this manuscript, and grants and personal fees from CSL Behring, Hansa Biopharma, Regeneron, and Amplyx outside the submitted work. Dr. Jordan has patents for the use of IL-6 inhibitors for desensitization and treatment of antibody-mediated rejection in transplant recipients, the use of clazakizumab to desensitize and improve renal transplantation in HLA-sensitized patients and to treat chronic antibody-mediated rejection of organ transplants, and the use of calcineurin inhibitor–free CTLA4-Ig with anti-IL-6/IL-6R for long-term immunosuppression in solid organ transplant recipients, all licensed to CSL Behring. All are outside the submitted work. Dr. Rouphael was supported by the Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) grant through the NIH/DAIT (5U19AI090023).
: This article does not contain any studies with human or animal subjects performed by any of the authors.
Free to read: This content has been made available to all.